Jun 2026 (Q2 FY26) — Aug 6, 2026
Organogenesis Holdings Inc. Q2 FY26 — Strategic Restructuring Amidst Market Contraction
Read the full callOrganogenesis Holdings (ORGO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Organogenesis Holdings earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 43.8 | −56.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -116.5 | −104.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -96.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.02 +2.00% · +$0.02
Performance −74.8% 1Y
1Y: $4.04 on 17 Oct 2025 → $1.02. High $6.54 (10 Nov 2025), low $1 (16 Oct 2026).
- Previous close
- $1
- 52-week range
- $1 – $6.54
- One year
- −75.00%
Overview
- Symbol
- ORGO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Organogenesis Holdings earnings calls (ORGO)
Financials
What the filings say
Net profit, year on year: −925% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 115 | 127 | 87 | 101 | 151 | 226 | 37 | 44 |
| Operating profit | 6 | 10 | -27 | -13 | 21 | 63 | -69 | -51 |
| Operating margin | 5.4% | 8.1% | −30.9% | −12.4% | 13.7% | 28.1% | −185.1% | −116.5% |
| Other income | -0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Interest | 0 | -0 | -1 | -1 | -0 | -0 | -0 | -0 |
| Profit before tax | 6 | 10 | -26 | -12 | 21 | 63 | -68 | -51 |
| Tax rate | −111.8% | 25.2% | 26.9% | 20.6% | −1.9% | 31.1% | 22.4% | −89.2% |
| Net profit | 12 | 8 | -19 | -9 | 22 | 44 | -53 | -96 |
| EPS ($ per share) | 0.09 | — | -0.17 | -0.10 | 0.11 | — | -0.44 | -0.77 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -130 | -171 | -155 | -61 | -45 | -41 | -40 | -3 |
| Total liabilities | 117 | 165 | 148 | 202 | 184 | 181 | 113 | 165 |
| Fixed assets | 40 | 47 | 56 | 79 | 102 | 116 | 89 | 104 |
| Total assets | 164 | 221 | 290 | 443 | 449 | 460 | 498 | 599 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -61 | -34 | 5 | 62 | 25 | 31 | 14 | -10 |
| Cash from investing | -2 | -6 | -23 | -31 | -34 | -24 | -10 | -14 |
| Cash from financing | 82 | 79 | 42 | -1 | -2 | -6 | 28 | -17 |
| Net cash flow | 19 | 39 | 24 | 30 | -11 | 1 | 32 | -42 |
| Capital expenditure | -2 | -6 | -18 | -31 | -34 | -24 | -10 | -14 |
| Free cash flow | -62 | -40 | -12 | 31 | -9 | 7 | 4 | -24 |
Insider filings
55 filings between Nov 24, 2025 and Mar 9, 2026.
Open market
decisions to buy or sellPurchases
$40.1K
2 purchases by 2 insiders
Sales
$2.62M
4 sales by 1 insider
Compensation
not trading decisions- 14
- Award — granted as compensation
- 35
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| NUSSDORF GLENN H | — | $2.62M | Dec 16, 2025 |
| Driscoll Michael Joseph | $26.7K | — | Mar 9, 2026 |
| Leibowitz Arthur S | $13.4K | — | Mar 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Mar 9, 2026 | Leibowitz Arthur S Director | Purchase | 5,000 | $13.4K |
| Mar 9, 2026 | Driscoll Michael Joseph Director | Purchase | 10,000 | $26.7K |
| Mar 1, 2026 | Cavorsi Robert Vice President, Strategy | Tax withheld | 700 | $2.2K |
| Feb 18, 2026 | Bilbo Patrick Chief Operating Officer | Tax withheld | 16,375 | $62.9K |
| Feb 18, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Award | 11,330 | $0 |
| Feb 18, 2026 | Gillheeney Gary S. President and CEO | Award | 188,856 | $0 |
| Feb 18, 2026 | Bilbo Patrick Chief Operating Officer | Award | 49,102 | $0 |
| Feb 18, 2026 | Gillheeney Gary S. President and CEO | Tax withheld | 91,311 | $350.6K |
| Feb 18, 2026 | Francisco David Chief Financial Officer | Award | 44,040 | $0 |
| Feb 18, 2026 | Cavorsi Robert Vice President, Strategy | Tax withheld | 5,487 | $21.1K |
| Feb 18, 2026 | Freedman Lori Chief Admin. and Legal Officer | Tax withheld | 14,411 | $55.3K |
| Feb 18, 2026 | Grow Brian Chief Commercial Officer | Award | 48,818 | $0 |
| Feb 18, 2026 | Cavorsi Robert Vice President, Strategy | Award | 16,454 | $0 |
| Feb 18, 2026 | Grow Brian Chief Commercial Officer | Tax withheld | 11,887 | $45.6K |
| Feb 18, 2026 | Freedman Lori Chief Admin. and Legal Officer | Award | 43,212 | $0 |
| Feb 18, 2026 | Francisco David Chief Financial Officer | Tax withheld | 14,687 | $56.4K |
| Feb 18, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Tax withheld | 3,778 | $14.5K |
| Feb 18, 2026 | Driscoll Michael Joseph Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Giacomin Jon L Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Duraibabu Prathyusha Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Lustig Garrett Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Leibowitz Arthur S Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Quintero Gilberto Director | Award | 48,828 | $0 |
| Feb 18, 2026 | Korfin Michele Ilene Director | Award | 48,828 | $0 |
| Feb 15, 2026 | Grow Brian Chief Commercial Officer | Tax withheld | 3,346 | $12.5K |
| Feb 15, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Tax withheld | 3,523 | $13.1K |
| Feb 15, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Tax withheld | 4,100 | $15.3K |
| Feb 15, 2026 | Francisco David Chief Financial Officer | Tax withheld | 21,412 | $79.9K |
| Feb 15, 2026 | Francisco David Chief Financial Officer | Tax withheld | 3,898 | $14.5K |
| Feb 15, 2026 | Grow Brian Chief Commercial Officer | Tax withheld | 18,910 | $70.5K |
| Feb 15, 2026 | Bilbo Patrick Chief Operating Officer | Tax withheld | 15,352 | $57.3K |
| Feb 15, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Tax withheld | 9,607 | $35.8K |
| Feb 15, 2026 | Montecalvo Antonio S. Vice President, Health Policy | Tax withheld | 1,389 | $5.2K |
| Feb 15, 2026 | Bilbo Patrick Chief Operating Officer | Tax withheld | 28,331 | $105.7K |
| Feb 15, 2026 | Bilbo Patrick Chief Operating Officer | Tax withheld | 5,114 | $19.1K |
| Feb 15, 2026 | Cavorsi Robert Vice President, Strategy | Tax withheld | 5,442 | $20.3K |
| Feb 15, 2026 | Cavorsi Robert Vice President, Strategy | Tax withheld | 6,667 | $24.9K |
| Feb 15, 2026 | Freedman Lori Chief Admin. and Legal Officer | Tax withheld | 13,510 | $50.4K |
| Feb 15, 2026 | Freedman Lori Chief Admin. and Legal Officer | Tax withheld | 12,761 | $47.6K |
| Feb 15, 2026 | Freedman Lori Chief Admin. and Legal Officer | Tax withheld | 24,428 | $91.1K |
| Feb 15, 2026 | Freedman Lori Chief Admin. and Legal Officer | Tax withheld | 4,043 | $15.1K |
| Feb 15, 2026 | Cavorsi Robert Vice President, Strategy | Tax withheld | 5,549 | $20.7K |
| Feb 15, 2026 | Gillheeney Gary S. President and CEO | Tax withheld | 85,605 | $319.3K |
| Feb 15, 2026 | Gillheeney Gary S. President and CEO | Tax withheld | 82,815 | $308.9K |
| Feb 15, 2026 | Gillheeney Gary S. President and CEO | Tax withheld | 78,646 | $293.3K |
| Feb 15, 2026 | Bilbo Patrick Chief Operating Officer | Tax withheld | 15,617 | $58.3K |
| Feb 15, 2026 | Gillheeney Gary S. President and CEO | Tax withheld | 24,340 | $90.8K |
| Feb 15, 2026 | Grow Brian Chief Commercial Officer | Tax withheld | 11,144 | $41.6K |
| Feb 15, 2026 | Grow Brian Chief Commercial Officer | Tax withheld | 10,559 | $39.4K |
| Feb 15, 2026 | Francisco David Chief Financial Officer | Tax withheld | 13,369 | $49.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Organogenesis Holdings Inc.
Free account. Everything above stays public.
Write why you follow Organogenesis Holdings Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading